The Luxembourg lender opens up new routes into private equity, credit and real assets for its European clients via ...

Interactive Chart for MERCK FINCK VA.AK.RE.UI A (UI25.BE), analyze all the data with a huge range of indicators.

Merck's (NYSE:MRK) top-selling drug – Keytruda's – impressive recent growth tells a compelling story, but it's one with a predictable ending. The pharmaceutical giant's remarkable performance ...

A brief summary - strong Buy, Buy, strong sell, sell or neutral signals for the Merck Finck Vermögensstrategie Defensiv Ui A fund. Access detailed technical analysis through moving averages buy/sell ...

0P0000RX3G Historical Data Get free historical data for 0P0000RX3G fund. You'll find the end of day price of the Merck Finck Stiftungsfonds Balanced Ui fund for the selected range of dates. The data ...

Deutsche Bank's Chief Investment Officer and chief strategist from private bank Merck Finck gives advice on how to protect assets against market volatility sparked by Trump's tariffs.

As for the prices of goods and services, US tariffs made a “further decline in inflation in the eurozone even more likely”, said Robert Greil, a strategist at private bank Merck Finck.

Merck Finck's expectation is in line with money market pricing. "In our view, the eurozone faces less of a threat from the inflation side than from the growth side," the chief strategist says.

Merck’s MRK fourth-quarter revenue grew 7% to $15.6 billion (including Keytruda growth of 21% to $7.8 billion), in line with overall 7% growth for the year. Shares fell more than 10% as Merck ...